Israel - hebreo - Ministry of Health

neopharm ltd - bazedoxifene as acetate 20 mg - coated tablets - bazedoxifene - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

Israel - hebreo - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

Israel - hebreo - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.06/06/2010 בקשה לשינוי משטר מינון the recommended dose is 500 mg at intervals of one month, with an additional 500 mg dose given two weeks after the initial dose.

Israel - hebreo - Ministry of Health

astrazeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

Israel - hebreo - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Israel - hebreo - Ministry of Health

merck serono ltd - follitropin alfa - אבקה להכנת תמיסה לזריקה - follitropin alfa 5.5 mcg/dose - follitropin alfa - follitropin alfa - 1) gonal-f followed by chorionic gonadotrophin (hcg) is recommended for the stimulation of follicular development and ovulation in women with hypothalamic-pituitary dysfunction who present with either oligomenorrhoea or amenorrhoea. these women are classified as w.h.o group ii patients and usually receive clomiphene citrate as primary therapy. they have evidence of endogenous oestrogen production and thus will either spontaneously menstruate or experience withdrawal bleeding after progestagen administration. polycystic ovarian disease (pcod) is part of the who ii classification and is present in the majority of these patients. 2) gonal-f is indicated for stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertillization (ivf) gamete intra-fallopian transfer (gift) and zogote intra-fallopian transfer (zift). 3) gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of sperma

Israel - hebreo - Ministry of Health

merck serono ltd - follitropin alfa - תמיסה להזרקה - follitropin alfa 600 iu/ml - follitropin alfa - follitropin alfa - gonal-f followed by chorionic gonadotrophin (hcg), is recommended for the stimulation of follicular development and ovulation in women with hypothalamic-pituitary dysfunction who present with either oligomenorrhoea or amenorrhoea. these women are classified as w.h.o group ii patients and usually receive clomiphene citrate as primary therapy. they have evidence of endogenous oestrogen production and thus will either spontaneously menstruate or experience withdrawal bleeding after progestagen administration. polycystic ovarian disease (pcod) is part of the who ii classification and is present in the majority of these patients. 2) gonal-f is indicated for stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertillization (ivf), gamete intra-fallopian transfer (gift) and zogote intra-fallopian transfer (zift). 3) gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermat

Israel - hebreo - Ministry of Health

bayer israel ltd - ethinylestradiol; levonorgestrel - טבליות מצופות - levonorgestrel 150 mcg; ethinylestradiol 30 mcg - progestogens and estrogens, fixed combinations - oral contraceptive.

Israel - hebreo - Ministry of Health

neopharm ltd - ethinylestradiol 0.03 mg; levonorgestrel 0.15 mg - tablets - progestogens and estrogens, fixed combinations - oral contraceptive

Israel - hebreo - Ministry of Health

novartis israel ltd - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant